[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100246520":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":24,"responsibleParty":28,"collaborators":24,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":24,"acronym":24,"eligibilityCriteria":37,"healthyVolunteers":34,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":24,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":53,"whyStopped":24,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":24},{"fullName":5,"class":6},"The First People's Hospital of Changzhou","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DC-CIK","EXPERIMENTAL","Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.",[13],"Biological: DC-CIK",{"label":15,"type":6,"description":16,"interventionNames":17},"IL-2\u002FIFN-α","Patients receive treatment of IL-2 or IFN-α.",[18],"Biological: IL-2\u002FIFN-α",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Patients with renal cell carcinoma will receive IL-2\u002FIFN-α by venous infusion.",[15],{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","xiaodong li","Principal Investigator","100246520","phase-2-dc-vaccine-therapy-combined-with-cytokine-induced-killer-cell-in-treating-100246520",false,"NCT02487550","DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating","Inclusion Criteria:\n\n* Histologically proven renal cell carcinoma\n* Age: \\> 18\n* WHO- ECOG Performance Status 0-1\n* At least one measurable tumor lesions according to the RECIST criteria.\n* Life expectancy more than 3 months\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal\u002Fsquamous cell carcinomas of the skin).\n* Patients with metastatic disease in the central nervous system (CNS).\n* Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.\n* Patients with acute or chronic infection including HIV.\n* Patients who are pregnant or nursing.\n* Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial.\n* Patients who receive corticosteroids or other immunosuppressive agents.\n* Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.","ALL","18 Years","80 Years",{"count":42,"type":43},1200,"ESTIMATED","INTERVENTIONAL",[46],"PHASE2","The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.",[49],"Renal Neoplasma",[51,52],"Renal neoplasma","CIK cells","NOT_YET_RECRUITING","2015-06-29",{"date":56,"type":43},"2015-07-01",{"date":58,"type":24},"2015-08",{"date":60,"type":43},"2030-07",{"name":5,"class":6}]